Implementing a Contingency Management Program Addressing Methamphetamine Use For and With the People of Hawaii

Queen's Medical Center

Status: Enrolling

Conditions: Methamphetamine Use Disorder; Contingency Managment

Treatments: Behavioral: Contingency Managment

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT06532370

U54GM138062 (U.S. NIH Grant/Contract)

RA-2024-019

Details and patient eligibility

About

The goal of this clinical trial is to use contingency management (CM) as an intervention tool to address methamphetamine use.

The main objectives are to:

• Gather effectiveness data on a pilot a CM program for participants in Hawaii who use methamphetamine following hospitalization due to traumatic injury
• To assess participant perspectives on engaging with a CM program based at a Level 1 Trauma Center. Researches will assess both patient-reported and biologically-confirmed medium-term program effectiveness and conduct qualitative interviews with participants post-program.

Participants will:

• Visit a follow-up clinic up to three times per week to complete urinalysis following discharge from the trauma unit
• Complete Treatment Effectiveness Assessments at 6 and 12-weeks
• Engage in a qualitative interview at the end of the CM program

Enrollment: 20 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Admitted trauma patients
• Age greater than 18 years old
• Urine drug screen positive for methamphetamines during the current hospitalization
• Report at least weekly methamphetamine use
• First methamphetamine use greater than 6 months prior to injury
• Report at least 4 DSM-V Amphetamine-Type Substance Use Disorder symptoms (at least moderate disease)
• Glasgow Coma Scale ≥13 upon arrival to the emergency department
• Ability to understand and participate in study procedures
• Ability to communicate in English

Exclusion criteria

• Active psychosis (reporting auditory or visual hallucinations)
• Under ongoing cardiorespiratory monitoring
• Evidence of moderate or severe traumatic brain injury
• Patients who are known to be pregnant
• Prisoner
• Individuals incarcerated at the time of their hospitalization
• Individuals lacking capacity to provide, or are otherwise unable or unwilling to provide written informed consent

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Contingency Managment

Experimental group

Description:

Participants are allowed to complete CM three times per week for the maximum of 12-weeks. At the six- and 12-week time points, participants will complete the Treatment Effectiveness Assessment (TEA) with study personnel.

Treatment:

Behavioral: Contingency Managment